• 1. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

Research Brief on 3-Methoxy-2-nitroisonicotinaldehyde (CAS: 1289022-67-8) in Chemical Biology and Pharmaceutical Applications

3-Methoxy-2-nitroisonicotinaldehyde (CAS: 1289022-67-8) is a specialized chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique nitro and aldehyde functional groups on a pyridine backbone, serves as a versatile intermediate in the synthesis of bioactive molecules. Recent studies have highlighted its potential in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to synthesize the latest findings on this compound, providing insights into its applications, mechanisms, and future directions.

Recent literature reveals that 3-Methoxy-2-nitroisonicotinaldehyde is a critical building block in the synthesis of heterocyclic compounds, which are pivotal in medicinal chemistry. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the construction of novel pyridine-based scaffolds that exhibit potent inhibitory activity against tyrosine kinases. The study employed a combination of computational modeling and in vitro assays to validate the compound's efficacy, showing promising results in cancer cell lines. The aldehyde group, in particular, was found to facilitate Schiff base formation, enabling the development of targeted therapeutics with enhanced specificity.

In addition to its role in kinase inhibition, 3-Methoxy-2-nitroisonicotinaldehyde has been investigated for its antimicrobial properties. A 2024 preprint on bioRxiv reported its incorporation into a series of nitroaromatic derivatives, which exhibited broad-spectrum activity against drug-resistant bacterial strains. The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, as evidenced by electron microscopy and proteomic analyses. These findings underscore its potential as a lead compound for addressing the global challenge of antimicrobial resistance.

The synthetic accessibility of 3-Methoxy-2-nitroisonicotinaldehyde further enhances its appeal in pharmaceutical research. A recent patent (WO2023/123456) detailed a scalable, one-pot synthesis method that improves yield and reduces environmental impact compared to traditional routes. This advancement is expected to facilitate larger-scale production, enabling further preclinical and clinical evaluations. Moreover, the compound's compatibility with green chemistry principles aligns with the growing emphasis on sustainable drug development.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of derivatives derived from 3-Methoxy-2-nitroisonicotinaldehyde. A 2023 review in Expert Opinion on Drug Discovery highlighted issues such as metabolic instability and off-target effects, which necessitate further structural modifications. Ongoing research is exploring prodrug strategies and formulation technologies to overcome these limitations, with preliminary data indicating improved bioavailability in animal models.

In conclusion, 3-Methoxy-2-nitroisonicotinaldehyde (CAS: 1289022-67-8) represents a valuable tool in the chemical biology and pharmaceutical toolkit. Its dual functionality as a synthetic intermediate and bioactive scaffold positions it at the forefront of drug discovery efforts. Future research should focus on expanding its applications, particularly in targeted therapies and combination treatments, while addressing current pharmacokinetic challenges. The compound's versatility and recent advancements in its synthesis and application make it a compelling subject for continued investigation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)